Literature DB >> 20931338

Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.

Marcus Franz1, K Grün, P Richter, B R Brehm, M Fritzenwanger, K Hekmat, D Neri, J Gummert, H R Figulla, H Kosmehl, A Berndt, A Renner.   

Abstract

Chronic cardiac rejection is represented by cardiac allograft vasculopathy (CAV) and cardiac interstitial fibrosis (CIF) known to cause severe complications. These processes are accompanied by remarkable changes in the cardiac extra cellular matrix (cECM). The aim of our study was to analyse the cECM remodelling in chronic rejection and to elucidate a potential role of ED-A domain containing fibronectin (ED-A(+) Fn), alpha smooth muscle actin (ASMA) and B domain containing tenascin-C (B(+) Tn-C). A model of chronic rejection after heterotopic rat heart transplantation was used. Allografts, recipient and control hearts were subjected to histological assessment of rejection grade, to real-time PCR based analysis of 84 genes of ECM and adhesion molecules and to immunofluorescence labelling procedures, including ED-A(+) Fn, ASMA and B(+) Tn-C antibodies. Histological analysis revealed different grades of chronic rejection. By gene expression analysis, a relevant up-regulation of the majority of ECM genes in association with chronic rejection could be shown. For 8 genes, there was a relevant up-regulation in allografts as well as in the corresponding recipient hearts. Association of ASMA positive cells with the grade of chronic rejection could be proven. In CAV and also in CIF there were extensive co-depositions of ED-A(+) Fn, ASMA and B(+) Tn-C. In conclusion, chronic cardiac allograft rejection is associated with a cECM remodelling. ASMA protein deposition in CAV, and CIF is a valuable marker to detect chronic rejection. Interactions of VSMCs and Fibro-/Myofibroblasts with ED-A(+) Fn and B(+) Tn-C might functionally contribute to the development of chronic cardiac rejection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931338     DOI: 10.1007/s00418-010-0750-6

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  72 in total

1.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

2.  TNF-alpha upregulates the expression of fibronectin in acutely rejecting rat cardiac allografts.

Authors:  A J Coito; J Binder; L F Brown; M de Sousa; L Van de Water; J W Kupiec-Weglinski
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

3.  Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis.

Authors:  Shin-Ichiro Morimoto; Kyoko Imanaka-Yoshida; Shinya Hiramitsu; Shigeru Kato; Masatsugu Ohtsuki; Akihisa Uemura; Yasuchika Kato; Toshio Nishikawa; Tetsuya Toyozaki; Hitoshi Hishida; Toshimichi Yoshida; Michiaki Hiroe
Journal:  J Pathol       Date:  2005-03       Impact factor: 7.996

4.  Diastolic function after cardiac and heart-lung transplantation.

Authors:  G Hausdorf; N R Banner; A Mitchell; A Khaghani; M Martin; M Yacoub
Journal:  Br Heart J       Date:  1989-08

Review 5.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

6.  Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque.

Authors:  K Wallner; C Li; P K Shah; M C Fishbein; J S Forrester; S Kaul; B G Sharifi
Journal:  Circulation       Date:  1999-03-16       Impact factor: 29.690

Review 7.  Cardiac allograft vasculopathy: current concepts, recent developments, and future directions.

Authors:  J D Hosenpud; G D Shipley; C R Wagner
Journal:  J Heart Lung Transplant       Date:  1992 Jan-Feb       Impact factor: 10.247

8.  Heterotopic rat heart transplantation: severe loss of glutathione in 8-hour ischemic hearts.

Authors:  André Renner; Martina R Sagstetter; Mario E Götz; Volkmar Lange; Dominik Bengel; Harry Harms; Peter Riederer; Olaf Elert
Journal:  J Heart Lung Transplant       Date:  2004-09       Impact factor: 10.247

9.  Heart transplantation in the United States, 1998-2007.

Authors:  J D Vega; J Moore; S Murray; J M Chen; M R Johnson; D B Dyke
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

Review 10.  Fibronectin in immune responses in organ transplant recipients.

Authors:  A J Coito; M de Sousa; J W Kupiec-Weglinski
Journal:  Dev Immunol       Date:  2000
View more
  11 in total

Review 1.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

Review 2.  Danger signals in regulating the immune response to solid organ transplantation.

Authors:  Jamie L Todd; Scott M Palmer
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

Review 3.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.

Authors:  Adam J Booth; Sherri C Wood; Ashley M Cornett; Alyssa A Dreffs; Guanyi Lu; Andrés F Muro; Eric S White; D Keith Bishop
Journal:  J Pathol       Date:  2012-01-04       Impact factor: 7.996

5.  De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Authors:  Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner
Journal:  J Mol Histol       Date:  2014-05-03       Impact factor: 2.611

Review 6.  The pathogenesis of cardiac fibrosis.

Authors:  Ping Kong; Panagiota Christia; Nikolaos G Frangogiannis
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

Review 7.  Advances in tenascin-C biology.

Authors:  Kim S Midwood; Thomas Hussenet; Benoit Langlois; Gertraud Orend
Journal:  Cell Mol Life Sci       Date:  2011-08-05       Impact factor: 9.261

8.  Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.

Authors:  Barbara Ziffels; Johanna Ospel; Katja Grün; Dario Neri; Alexander Pfeil; Michael Fritzenwanger; Hans R Figulla; Christian Jung; Alexander Berndt; Marcus Franz
Journal:  Dis Markers       Date:  2016-08-18       Impact factor: 3.434

9.  Comparative mRNA and MicroRNA Profiling during Acute Myocardial Infarction Induced by Coronary Occlusion and Ablation Radio-Frequency Currents.

Authors:  Eduardo T Santana; Regiane Dos Santos Feliciano; Andrey J Serra; Eduardo Brigidio; Ednei L Antonio; Paulo J F Tucci; Lubov Nathanson; Mariana Morris; José A Silva
Journal:  Front Physiol       Date:  2016-11-25       Impact factor: 4.566

10.  Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.

Authors:  Marcus Franz; Katja Grün; Stefan Betge; Ilonka Rohm; Bernadin Ndongson-Dongmo; Reinhard Bauer; P Christian Schulze; Michael Lichtenauer; Iver Petersen; Dario Neri; Alexander Berndt; Christian Jung
Journal:  Oncotarget       Date:  2016-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.